Our innovative TapBoost Technology can be used for a wide variety of applications
Experimental, therapeutic, and commercial applications require the production of high-quality recombinant proteins at a certain scale. However, generating the desired quality and amount of recombinant proteins can be a challenging task especially when the protein is a “difficult-to-express” protein, which often occurs. These proteins are often unstable due to protein folding problems. In case of membrane proteins and secreted proteins, they are confined in the endoplasmic reticulum (ER). With TapBoost, the expression level of target recombinant proteins can be significantly increased. Learn more.
Therapeutic recombinant proteins including antibodies have been used for a wide range of indications. The revenue for protein-based therapeutics is expected to expand at an annualized rate of 13.5% per year and the expected value (in sales) of this market is predicted to be $498 billion by 2020 (Research and Markets, Nov 2013). Therapeutic recombinant proteins are widely produced in cells called host cells. Proper structure of the expressed proteins is essential for their biological function and proteins with a structural defect are promptly detected by the host cell (cellular quality control system) and eventually degraded. Therefore, protein folding systems and cellular quality control systems have a significant impact on the production of recombinant proteins. Many technologies have been developed to control these systems but these approaches act on all secreted proteins being made by the host cell with unwanted cellular effects that limit the applicability and efficiency of these technologies. Learn more.
Therapeutics (peptide, gene, and cell therapy)
Protein folding problems and quality control systems are emphasized not only in exogenous protein expression but also in endogenous protein expression. In fact, many diseases are brought on as a result of abnormal protein folding and/or a strict cellular quality control system. These diseases are called “conformational diseases.” A large number of diseases are now recognized as conformational diseases, including cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, and alpha-1 antitrypsin deficiency. Learn more.